X

Trial Profile

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Malignant melanoma
Focus Biomarker; Therapeutic Use

Most Recent Events

16 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2025.
16 Dec 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2025.
01 Jul 2020 Results (n=25) in the sub-study assessing HRQOL, psychosocial and neurocognitive outcome in survivors of metastatic melanoma treated with pembrolizumab, published in the Supportive Care in Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com